Report Overview

The global CAR T-Cell therapy market size stood at around USD 482.2 million in 2019 and is projected to reach USD xx million by 2028, exhibiting a CAGR of xx% during the forecast period.

In the recent years, cancer has become one the major cause of deaths worldwide and companies are coming up with various conventional and cytotoxic immunotherapies in the market. Keeping into consideration the complex behaviour of tumours and the involvement of varied genetic and cellular factors in tumorigenesis and metastasis, companies are focusing on developing new treatments which would focus on targeting tumours at both genetic and cellular level.

Chimeric Antigen Receptor (CAR) T cell therapy is one such novel therapeutic treatment which comprises reengineering cancer patient's white blood cells (WBC) to fight the malignant cells by recognizing them. During this therapy, the persons T cells are extracted, preciously reformed and then inserted again to the person's body where the restructured cell multiply and target cancer cells.



Market Drivers and Restraints

Growing prevalence of cancer across the world, technological advancement for advanced & reliable treatment for cancer, and rise in the number of cell therapy clinical studies are driving the growth of the global CAR T cell therapy market. Drastic rise in CAR T-Cell trials also acts as a driver for the market growth.

However, side effects and high cost of treatment of CAR T-Cell therapy are key restraints for the market growth.

Major CAR T-Cell Therapy Market by Disease Indication

The major disease includes Diffuse Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Follicular Lymphoma and Others.

It is estimated that the market for DLBCL has the highest market share and is estimated to grow at a CAGR of 22.9% during the forecast period. The market for Multiple myeloma is also expected to grow at a faster pace reaching approximately USD 4.2 billion by 2028. The first therapy approved was in paediatrics and/or young adults Acute Lymphoblastic leukaemia (ALL), an ailment with a high unmet need where CAR-T indicated high effectiveness, nonetheless, which represents a very small patient population.